Search results
Showing 16 to 30 of 75 results for exchange
Routine antenatal anti-D prophylaxis for women who are rhesus D negative (TA156)
Evidence-based recommendations on routine anti-D prophylaxis for women who are rhesus D negative.
View recommendations for TA156Show all sections
Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)
Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children.
We work with the clinical classifications service of NHS Digital to provide relevant clinical coding information for interventional procedure and medical technologies guidance.
Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7)
Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency.
Corneal inlay implantation for correction of presbyopia (HTG311)
Evidence-based recommendations on corneal inlay implantation for correction of Presbyopia. This involves placing a disc inside a flap or pocket made in the cornea to improve near vision.
View recommendations for HTG311Show all sections
Sections for HTG311
Insertion of endobronchial nitinol coils to improve lung function in emphysema (HTG370)
Evidence-based recommendations on insertion of endobronchial nitinol coils to improve lung function in emphysema. This involves inserting coils to reduce airflow to damaged parts of the lung.
Lung volume reduction surgery for advanced emphysema (HTG69)
Evidence-based recommendations on lung volume reduction surgery for treating advanced emphysema. This involves removing damaged lung tissue using a special stapling device, a laser, or both.
View recommendations for HTG69Show all sections
Sections for HTG69
Extracorporeal membrane oxygenation (ECMO) in postneonatal children (HTG17)
Evidence-based recommendations on extracorporeal membrane oxygenation in postneonatal children. This involves connecting the child's internal circulation to an external blood pump and artificial lung.
View recommendations for HTG17Show all sections
Sections for HTG17
Evidence-based recommendations on inducing and maintaining normothermia using temperature modulation devices after stroke or subarachnoid haemorrhage in adults. This involves cooling the body using pads placed on the skin or tubes put into the body.
View recommendations for HTG587Show all sections
International collaboration with NICE
Extracorporeal whole liver perfusion for acute liver failure (HTG573)
Evidence-based recommendations on extracorporeal whole liver perfusion for acute liver failure. This involves blood being diverted to a whole liver (perfusion) outside the body and returned to the patient.
View recommendations for HTG573Show all sections
Evidence-based recommendations on ex-situ machine perfusion for extracorporeal preservation of lungs for transplant. This involves using a machine to deliver an oxygenated solution to a donor lung and keep it at normal body temperature until it can be transplanted.
View recommendations for HTG580Show all sections
Temperature control to improve neurological outcomes after cardiac arrest (HTG710)
Evidence-based recommendations on temperature control to improve neurological outcomes after cardiac arrest. This involves controlling a person’s body temperature while they are still unconscious after their heart has been restarted. Either their body is kept at a normal temperature of between 36.5°C and 37.5°C to prevent fever, or it is cooled to between 32.0°C and 36.0°C (therapeutic hypothermia).
View recommendations for HTG710Show all sections
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)
NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .
Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)
This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.